# Steroidomic Changes in the Cerebrospinal Fluid of Women with Multiple Sclerosis

## TL;DR

This study found changes in steroid levels in the cerebrospinal fluid of women with multiple sclerosis, which may be linked to disease severity and progression.

## Contribution

The study identifies specific steroidomic alterations in MS patients and links them to potential pathophysiological mechanisms.

## Key findings

- Unconjugated steroids are lower in MS patients, suggesting altered steroid sulfotransferase activity.
- Altered levels of steroids linked to CYP11B1 function are associated with more severe MS.
- Reduced levels of protective steroids like pregnenolone and DHEA correlate with worse MS outcomes.

## Abstract

Multiple sclerosis (MS) is a long-term disease that causes inflammation and damage to the nervous system. This study evaluated steroidomic alterations related to MS in 57 female MS patients during the follicular phase and 17 during the luteal phase, as well as in age- and phase-matched controls. The data showed that (1) unconjugated and conjugated steroids were strongly linked between the blood and CSF. (2) MS patients have lower levels of unconjugated steroids compared to controls. However, unchanged levels of conjugated steroids suggest a possible increase in steroid sulfotransferase functioning. (3) MS patients show altered levels of steroids linked to 11β-hydroxylase (CYP11B1) function. While direct enzyme activity was not measured, disrupted cortisol biosynthesis—potentially linked to reduced functioning of both CYP11B1 and 17α-hydroxylase/17,20-lyase—is associated with more severe cases of MS. (4) Reduced levels of 5α/β-steroids and protective GABAergic 3α-hydroxy-5α/β-steroids in MS patients might be linked to the pathophysiology of MS. (5) A potential increase in AKR1C3 function in MS could contribute to inflammation, as this enzyme catalyzes the synthesis of both steroids and prostaglandins. However, direct measurements of enzyme activity are needed to confirm this hypothesis. (6) Lower pregnenolone levels in MS patients might weaken neuroprotection, while higher pregnenolone sulfate levels could support cognitive function. (7) Lower levels of protective pregnenolone, DHEA, and androstenediol were associated with worse MS, suggesting these steroids may help shield against the disease.